What is the revenue and EPS growth rate for Inogen year over year?

What were the key takeaways from Inogen’s earnings call?

What is Inogen's latest dividend and current dividend yield?

Did Inogen beat or miss consensus estimates last quarter?

What factors drove the changes in Inogen's revenue and profit?

What were the key takeaways from Inogen's earnings call?

What is Inogen's gross profit margin?

What does Inogen do and what are its main business segments?

- **Revenue Recovery**: Full-year 2025 revenue growth of 4%, with Q4 unit volumes up 20% YoY. 
- **Profitability Milestone**: First positive adjusted EBITDA ($2.7M) since 2021, net loss reduced 61%. 
- **Innovation Surge**: $6M+ in Simeox sales, Voxi 5 early traction, and Aurora masks targeting $2.2B market. 
- **Share Buyback**: $30M authorized to capitalize on undervalued shares. 
- **2026 Outlook**: 6% revenue growth guidance, with focus on B2B POC and new product launches.

**【CEO Summary Section】**
- **Revenue Growth**: Q4 2025 revenue of $81.7 million, full-year $348.7 million, reflecting 4% YoY growth. Unit volumes grew 20% YoY, driven by POC adoption. International sales grew 15% YoY to $32.5 million.
- **Strategic Priorities**: 
  - **Top-Line Growth**: Focus on U.S. B2B channel (60% of new POC starts) and international expansion. 
  - **Profitability**: Achieved first positive adjusted EBITDA ($2.7 million) since 2021, with net loss narrowing 61% to $8 million. 
  - **Innovation**: Launched Simeox (airway clearance), Voxi 5 (stationary O2), and Aurora CPAP masks. TAM expanded from $400M to $3.4B.
- **New Products**: Simeox generated $6M in 2025, Voxi 5 shows early traction, and Aurora targets $2.2B sleep apnea market.
- **Share Repurchase**: $30M authorized program to enhance shareholder value.

**【CFO Financial Commentary】**
- **Q4 2025 Results**: 
  - Total revenue $81.7M (-2% YoY), driven by delayed U.S. orders ($120M+ pipeline). 
  - Gross margin 43.1%, down 220bps due to channel mix. 
  - Adjusted EBITDA (-$1.7M vs. -$3.6M YoY). 
  - Cash balance $120.9M, 0 debt.
- **2026 Guidance**: 
  - Revenue $366-373M (+6% YoY). 
  - Continued EBITDA improvement, with R&D investments. 
  - Q1 2026 revenue flat YoY, with B2B growth offsetting DTC decline.
- **Margins**: Target high single-digit revenue growth and 10%+ EBITDA over 3-5 years.

**【Q&A Highlights】**
- **Order Timing**: Shifted orders (~$120M) to H1 2026, with Q1 shipments already underway. 
- **DTC Channel**: Q4 DTC down 15% YoY, but improving sequentially (-27% Q1 → -15% Q4). 
- **Aurora Masks**: Back-end loaded 2026 ramp, targeting $20M+ annual opportunity. 
- **Simeox Growth**: $6M 2025 (all international), with China launch pending and U.S. trial underway. 
- **EBITDA Cadence**: Q2/Q3 expected to be strongest, with Q1/Q4 more challenging due to seasonality and R&D spend.

Inogen, Inc.(INGN)-20260225-2025 Q4 Earnings call transcript

**Key Takeaways**
- **Revenue Momentum**: Q3 2025 revenue of $92.4 million, driven by 18.8% international B2B growth and 6.6% domestic B2B expansion.
- **Profitability Improvement**: Adjusted EBITDA of $2.3 million, up from $0.5 million, with operating expenses down 1.4%.
- **Innovation Breakthrough**: Voxi 5 launch targets 90% of oxygen therapy patients, with 2026 revenue impact. Simeox trials advancing in Europe and China.
- **Strategic Growth**: COPD market presents $600 million opportunity, with international expansion into Europe and China planned.

**【CEO Summary Section】**
- **Revenue Growth**: Reported $92.4 million in Q3 2025, marking the 7th consecutive quarter of mid-single-digit growth. Domestic B2B revenue increased 6.6% to $24.9 million, while international B2B rose 18.8% to $38.4 million.
- **Strategic Priorities**: Focused on top-line growth, profitability, and innovation. Launched Voxi 5, a stationary oxygen concentrator, to expand into the 90% of patients needing stationary units. Progress on Simeox, a bronchial decongestion solution, with limited U.S. market release and trials in Europe and China.
- **Market Expansion**: International B2B growth driven by Europe and new geographies, with China as a future target. COPD market presents a $600 million conversion opportunity.

**【CFO Financial Commentary】**
- **Financial Results**: GAAP net loss of $5.3 million (down from $6 million), adjusted EBITDA of $2.3 million (up from $0.5 million). Operating expenses decreased 1.4% to $48.4 million. Positive operating cash flow of $4.6 million (excluding one-time expenses).
- **Gross Margin**: 44.7%, down 182 basis points due to higher B2B sales mix. Rental gross margin declined 470 basis points, partly due to Medicare mix and capped patients.
- **Guidance**: Full-year revenue expected $354-357 million (6% YoY growth), adjusted EBITDA $2 million. Q4 revenue projected $87-90 million (10% YoY growth).

**【Q&A Key Highlights】**
- **International Growth**: Europe led Q3 expansion, with new markets planned. China entry in progress via UL Medical partnership.
- **Voxi 5**: Minimal Q3 impact, significant 2026 contribution. Targets 90% of oxygen therapy patients needing stationary units.
- **Simeox**: European and Chinese trials for reimbursement. U.S. limited market release building clinician awareness.
- **Rental Margin**: Pressure from Medicare mix and capped patients, but stabilization expected. One-time logistic adjustment impacted Q3 margins.

Inogen, Inc. (INGN) Q3 2025 Earnings Call Transcript

- **Revenue Growth Momentum**: $92.3M Q2 revenue (+4% YoY), driven by 19.3% B2B growth and 17.7% international expansion.
- **Voxi 5 Launch Success**: Stationary concentrator expected to drive Q4 growth, with 19% sequential DTC improvement.
- **Profitability Milestones**: 2nd consecutive $2.1M adjusted EBITDA profit, targeting full-year breakeven.
- **Strategic Initiatives**: Digital health tools and Simeox trials advancing, with $123.7M cash balance supporting execution.

**【CEO Summary Section】**
- Q2 2025 revenue of $92.3 million (+4% YoY), driven by 19.3% growth in domestic B2B and 17.7% in international B2B.
- Launched Voxi 5 stationary oxygen concentrator, targeting long-term care patients and expanding addressable market share.
- Achieved 6th consecutive quarter of mid-single-digit revenue growth, with 19% unit growth from POC adoption.
- Reduced operating expenses by 4.7% to $47.5 million, with $2.1 million adjusted EBITDA (2nd consecutive profitable quarter).
- Full-year 2025 guidance: $354-357 million revenue (+6% midpoint), with adjusted EBITDA breakeven.

**【CFO Financial Commentary】**
- Gross margin 44.8% (-335bps YoY) due to higher B2B mix, but +60bps sequentially from volume leverage.
- Generated $4.4 million operating cash flow, +$1.2 million in cash balance to $123.7 million.
- Q3 2025 revenue guidance: $91-93 million (+4% midpoint), with Q4 expected to drive 7% growth.

**【Q&A Highlights】**
- Voxi 5 expected to contribute meaningfully in Q4 2025, with potential for double-digit growth in Q4.
- Simeox clinical trials progressing for reimbursement data, with no external timing guidance.
- DTC channel improved 19% sequentially, with focus on efficiency and profitability.
- Digital health portal enhances patient engagement, with early adopter positive feedback.

Inogen, Inc. (INGN) Q2 2025 Earnings Call Transcript

- **Revenue Resilience**: Q1 2025 revenue growth of 5.5% driven by B2B expansion, offsetting DTC contraction. Full-year guidance reaffirmed at 5-6% growth.
- **Profitability Milestone**: First positive adjusted EBITDA ($36,000) since Q1 2021, with full-year breakeven target.
- **Strategic Expansion**: UL Medical collaboration unlocks China market access and enhances U.S. product offerings, supported by $27M equity investment.
- **Cash Strength**: $122.5M cash balance provides liquidity for growth initiatives despite $13M Simeox-related earn-out payment.
- **Rental Channel Recovery**: Sequential rental revenue improvement signals stabilization, with private payer mix challenges easing.

**【CEO Summary Section】**
- Q1 2025 revenue reached $82.3 million, up 5.5% YoY, driven by B2B channels (domestic +29.9%, international +22.9%) and offset by DTC sales decline (-26.8%).
- Announced collaboration with UL Medical to expand into China and enhance U.S. product portfolio, with UL acquiring 9.9% stake via $27M investment.
- Achieved positive adjusted EBITDA ($36,000) for first time since Q1 2021, with full-year breakeven guidance maintained.
- Simeox FDA clearance milestone met, triggering $13M earn-out payment to Physio Assist.

**【CFO Financial Commentary】**
- GAAP net loss narrowed to $6.2M (-57% YoY), with Non-GAAP EPS improving to -$0.11 (-76% YoY).
- Gross margin stabilized at 44.2%, up 15bps YoY, despite rental margin decline.
- Operating expenses decreased 13.1% YoY to $44M, reflecting cost control and restructuring.
- Full-year 2025 revenue guidance: $352-355M (5-6% growth), with Q2 outlook of $89-91M.
- Cash position remains strong at $122.5M with no debt.

**【Q&A Highlights】**
- **Rental Channel**: Sequential improvement in Q1 ($13.8M vs. $14.9M YoY), with private payer mix stabilizing. Gross margin benefited from operational efficiency gains.
- **DTC Channel**: Smaller, optimized team leading to higher rep productivity (+units, +revenue, -returns). Full-year comps to normalize in H2 2025.
- **Tariffs**: Current exemptions protect margins, but monitoring ongoing trade developments.
- **Innovation Pipeline**: Simeox limited commercial release underway; digital health updates expected later in 2025.

Inogen (INGN)-7 May 25-2025 Q1 Earnings call transcript

- **Revenue Resilience**: 6.4% YoY growth driven by B2B expansion, offsetting DTC contraction.
- **Yuwell Synergy**: $27M investment bolsters balance sheet; product exchange to tap China and U.S. stationary oxygen markets.
- **Margin Improvement**: Q4 2024 adjusted EBITDA improved 79% YoY; targeting 2025 breakeven with 43-45% gross margin.
- **Innovation Momentum**: Simeox FDA clearance and Rove 4 launch expand addressable patient base; digital health updates enhance remote monitoring.
- **Risks & Challenges**: DTC recovery delayed until 2025H2; Simeox integration causes 100 bps margin headwind in 2025.

**【CEO Summary Section】**
- **2024 Revenue Growth**: Total revenue reached $335.7 million, up 6.4% YoY, driven by B2B channels (domestic +24.1%, international +31.5%). DTC sales declined 21.3% due to downsized sales force.
- **Yuwell Collaboration**: $27 million investment from Yuwell (9.9% stake) and strategic product exchange to expand into China and U.S. stationary oxygen market.
- **Product Launches**: FDA clearance for Simeox airway device and launch of Rove 4 POC, with digital health updates for remote monitoring.
- **Profitability Progress**: Achieved 2 quarters of adjusted EBITDA profitability in 2024; targeting breakeven in 2025 through cost management and Yuwell synergies.

**【CFO Financial Commentary】**
- **Q4 2024 Financials**: 
  - Revenue: $80 million (+5.5% YoY)
  - GAAP Net Loss: $9.8 million (-63% YoY)
  - Adjusted EBITDA: -$3.6 million (+79% YoY improvement)
  - Gross Margin: 45.3% (+821 bps YoY)
- **2025 Outlook**: 
  - Revenue: $352-355 million (+5-6% YoY)
  - Gross Margin: 43-45% (impacted by Simeox/Yuwell integration)
  - Target: Adjusted EBITDA breakeven by year-end
- **Balance Sheet**: $117.4 million cash post-Yuwell investment, no debt.

**【Q&A Key Takeaways】**
- **Yuwell Impact**: 100 bps margin headwind in 2025 due to product integration, but long-term benefits from shared supply chain and market access.
- **Channel Mix**: B2B growth (domestic +24%, intl +31%) offset DTC decline; DTC recovery expected in 2025H2 as sales force stabilizes.
- **Simeox Strategy**: Limited launch in 2025 with focus on U.S. reimbursement; leverages existing sales channels for recurring disposable revenue.
- **Rental Challenges**: Private payer mix reduces margins; exploring pricing strategies to improve profitability.
- **Tariff Risk**: Minimal impact as manufacturing is U.S.-based; monitoring regulatory developments.


Actual											-0.07	0.12	-0.08	-0.23	-0.03	0.22	0.53	-1.01	-0.62	-0.15	-0.42	-2.47	-0.88	-0.42	-1.97	-1.14	-0.62	-0.24	-0.25	-0.41	-0.25	-0.15	-0.2	-0.26
Forecast											-0.1117	-0.0767	0.018	-0.2667	-0.2683	-0.11	-0.25	-0.728	-0.475	-0.37	-0.42	-0.574	-0.7803	-0.594	-1.2135	-0.6257	-0.7571	-0.4642	-0.4957	-0.6076	-0.4426	-0.2667	-0.2078	-0.3574
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	+37.33%	+256.45%	-544.44%	+13.76%	+88.82%	+300.00%	+312.00%	-38.74%	-30.53%	+59.46%	0.00%	-330.31%	-12.78%	+29.29%	-62.34%	-82.20%	+18.11%	+48.30%	+49.57%	+32.52%	+43.52%	+43.76%	+3.75%	+27.25%

INGN

INGN fundamentals

INGN Q4 2025 Earnings

Earnings Call

You can ask Aime

INGN

INGN fundamentals

INGN Q4 2025 Earnings

Earnings Call

INGN Earnings Call Summary for Q4/20256:00 PM on Feb 24, 2026

INGN Earnings Call Summary for Q3/20258:30 AM on Nov 5, 2025

INGN Earnings Call Summary for Q2/20255:00 PM on Aug 7, 2025

INGN Earnings Call Summary for Q1/20255:00 PM on May 7, 2025

INGN Earnings Call Summary for Q4/20245:00 PM on Feb 25, 2025

You can ask Aime